InflaRx N.V. (NASDAQ:IFRX) Receives $7.50 Consensus Price Target from Brokerages

InflaRx N.V. (NASDAQ:IFRX) has been given a consensus recommendation of “Moderate Buy” by the eight research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $7.50.

IFRX has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of InflaRx in a report on Tuesday, December 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a research report on Monday, December 29th. Leerink Partnrs cut InflaRx from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 3rd. Raymond James Financial restated an “outperform” rating on shares of InflaRx in a research report on Wednesday, December 31st. Finally, Wall Street Zen cut InflaRx from a “hold” rating to a “sell” rating in a report on Saturday, November 8th.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Concurrent Investment Advisors LLC bought a new position in shares of InflaRx during the 2nd quarter valued at $65,000. Bank of America Corp DE purchased a new stake in InflaRx during the third quarter valued at about $3,316,000. Boothbay Fund Management LLC grew its stake in shares of InflaRx by 10.8% during the third quarter. Boothbay Fund Management LLC now owns 175,114 shares of the company’s stock valued at $235,000 after buying an additional 17,056 shares during the last quarter. ADAR1 Capital Management LLC purchased a new position in shares of InflaRx in the third quarter worth about $214,000. Finally, Squarepoint Ops LLC lifted its stake in shares of InflaRx by 29.1% in the 3rd quarter. Squarepoint Ops LLC now owns 188,523 shares of the company’s stock valued at $253,000 after acquiring an additional 42,489 shares during the last quarter. 42.39% of the stock is owned by hedge funds and other institutional investors.

InflaRx Price Performance

Shares of NASDAQ IFRX opened at $1.00 on Friday. The stock’s 50-day simple moving average is $1.13 and its two-hundred day simple moving average is $1.15. InflaRx has a twelve month low of $0.71 and a twelve month high of $2.77. The firm has a market capitalization of $67.13 million, a P/E ratio of -1.47 and a beta of 1.44.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16). The business had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.03 million. As a group, research analysts anticipate that InflaRx will post -1.04 EPS for the current fiscal year.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.